The most recent focus of attention in this field is the arrival of biologics. Recently, biologics-related activities, which include consulting for the introduction of biologics, explanatory sessions at the introduction of biologics, pre-treatment examinations and regular administration of adalibumab, have been gradually increasing. In consultations I endeavor to take the time to explain the effects, side-effects and costs, which require detailed explanations. Another new biologic, ustekinumab, was approved by the relevant ministry in March 2011. It seems to me that cases for which biologics will be administered at the outpatient clinic will continue to increase. At the clinic I have many patients who are administered with etretinate or cyclosporin. Feel free to make referrals for refractory psoriasis cases.